Volume | 8,665,313 |
|
|||||
News | - | ||||||
Day High | 50.43 | Low High |
|||||
Day Low | 49.775 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
50.32 | 49.775 | 50.43 | 50.23 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
74,009 | 8,665,313 | US$ 50.05 | US$ 433,681,932 | - | 48.252 - 81.24 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:43:01 | 42 | US$ 49.85 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
101.68B | 2.03B | - | 46.16B | 6.33B | 3.11 | 16.07 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 49.06 | 50.755 | 48.252 | 49.67 | 13,878,963 | 0.795 | 1.62% |
1 Month | 52.65 | 52.65 | 48.252 | 49.90 | 13,624,321 | -2.80 | -5.31% |
3 Months | 60.25 | 60.58 | 48.252 | 53.88 | 13,224,064 | -10.40 | -17.25% |
6 Months | 66.27 | 66.38 | 48.252 | 57.83 | 11,422,660 | -16.42 | -24.77% |
1 Year | 80.70 | 81.24 | 48.252 | 63.04 | 9,840,946 | -30.85 | -38.22% |
3 Years | 62.19 | 81.435 | 48.252 | 65.99 | 11,032,386 | -12.34 | -19.83% |
5 Years | 52.16 | 81.435 | 41.19 | 60.72 | 12,410,435 | -2.31 | -4.42% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |